Omnicare — Q4 2011 Earnings Presentation
18 slides from Omnicare's earnings presentation, Feb 23, 2012
Slide 1: Fourth Quarter and Full Year 2011 Financial Results
Slide 2: Forward-Looking Statements
Forward-Look Statements Certain of listed within looki statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-| Hooking i but are not tite to, i belief or fion. Such fe it uncertainties, materially from those stated. The most significant of is it bed in
Slide 3: Table of Contents
Table of Contents Fourth Quarter 2011 Highlights. .. Operating Metrics — Script Data... Operating Metrics — Bed Data Definition Change... Operating Metrics — Long-Term Care Bed Data... Adjusted Operating Profit by Segment. Adjusted Gross Profit & Net Income... Cash Flows. Cash Deployment.. Capital S
Slide 4: Fourth Quarter 2011 Highlights
Fourth Quarter 2011 Highlights Gross profit increased 3.9% sequentially to $359.7M on 0.8% increase in sales — Gross margin sequentially higher by 69 bps to 23.1%, reflecting a higher generic dispensing rate Adjusted EBITDA") increased 3.6% sequentially to $162.9M Adjusted EPS") of $0.58 vs. $0.54 i
Slide 5: Operating Metrics: Script Data
Operating Metrics Script Data Sequential Prior Year Increase / Increase / (In thousands, except %s) 4.2011 3Q2011 (Decrease) _4Q2010_ (Decrease) Long-Term Care Group Scripts: Generic scripts dispensed 20,049 19,535 2.6% 19,356 3.6% Branded soripts dispensed 5265 5,317 (1.0%) 6,054 (13.0%) Over-the-c
Slide 6: Operating Metrics: Bed Data Definition Change
Operating Metrics Bed Data Definition Change As Omnicare moves to reporting two segments, we will report bed count only in Long-Term Care: — Improve segment transparency and facilitate more accurate analyst modeling (LTC beds positively correlated to revenues, while specialty revenues generally aren
Slide 7: Operating Metrics: Long-Term Care Bed Data
Operating Metrics Long-Term Care Bed Data Sequential Prior Year Increase / Increase / (In thousands) 4Q2011_ _3Q2011_ (Decrease) _4Q2010 (Decrease) Beginning of period - Total Beds") 1,378 1,376 2 1,385 (7) Specialty beds & other® (370) (374) (4) (357) 13 Beginning of period - LTC Beds 1,008 1,002 6
Slide 8: Adjusted Operating Profit by Segment
Adjusted Operating Profit by Segment ()@) Sequen YTD YTD Increase / In millions, except %s 121/11 _12/3110__ (Decrease) Long-Term Care Group Net sales $5,1235 $5,175.7 (1.0%) Adjusted operating profit 546. 6 (0.5%) Rate 10.67% 10.62% 5 bps In whole nur Per script data Sales / script © $ 445 $ 45.2 (
Slide 9: Adjusted Gross Profit & Net Income
Adjusted Gross Profit & Net Income (1) ___Sequential___ Prior Year, Increase / Increase / ‘In milions, except per share data and %s _4Q.2011_ _3Q2011_ (Decrease) _40 2010 (Decrease) Not sales S1S87T $1,544.48 0.8% $ 1,500.7 1.7% Cost of sales 11974 1,198.8 (0.1%) 1,198.4 0.1% ‘Adjusted gross profit
Slide 10: Cash Flows
Cash Flows (1) Sequential Prior Year Increase / Increase | In millions, except %s 4.2011 30.2011 (Decrease) 4Q 2010 (Decrease) Net income (loss) $ 312 $ 279 S$ 65.3) 147, Loss from discontinued operations 99 a: 2%) 82 (13. 0) 115 11.6 (0.9%) 11.9 (3.4%) 243 0-212 14.6% 203 19.7% 5.0 (84.0%) 46 (82.6
Slide 11: Cash Deployment
Cash Deployment Increase / D D Increase / In milions, except %s 4Q2011 402010 (Decrease) _12/31/11_ _12/31/10 (Decrease) Net cash flows from operating activities of continuing operations (reported) $1015 $ 997 1.8% $ 549.4 § 368.9 48.9% Capital expenditures 237 52 355.8% 628 235 167.2% Acquisitions
Slide 12: Capital Structure
Capital Structure Major Debt Maturity Schedule“ (in $ millions) | wAs of 12/31/09 | BAs of 12/31/11 2010 2015 2020 2025 2030 2035 ues due 2085 ae nym 2015 wih lee oe cape nelided an of namo debt amount
Slide 13: Full-Year 2012 Guidance
Full-Year 2012 Guidance FY2012 % Change Guidance) > Revenue® $6.2B $6.1B to $6.2B -1.6% to 0.0% + Adjusted Diluted EPS@)@) $2.13 $2.37 to $2.47 11.3% to 16.0% * Cash Flow from Operations $549.4M $400M to $500M_ -27.2% to -9.0%
Slide 14: Longer-Term Targets
Longer-Term Targets “) a + Adjusted Diluted EPS (old methodology) cae a ute WTO eeu + Cash Flow from Operations $400-$500 million annually + Capital Returned to Shareholders Approximately 25% per year?) Focus on continued debt reduction, management of maturity schedules * Capital Structure
Slide 15: Appendix
Slide 16: Working Capital Management
Working Capital Management Five Quarter Trend 40 Ba si But CO —S——<—<—<— ee ”— ° 27.6 63.5 61.4 59.9 10 Tr 57 oO 51 sano 1011 ant sant sant
Slide 17: Selected Branded Drug Patent Expirations
Selected Branded Drug Patent Expirations) FY2012 Actos Comtan Diovan Geodon Lexapro Lidoderm Plavix Provigil Seroquel Singulair Xopenex FY 2013 Aciphex Asacol Cymbalta Fragmin Humalog Lovaza Lupron Depot Niaspan Renagel Travatan Tricor FY 2014 Actonel Avelox Celebrex Copaxone Inj. Evista Flovent Inv
Slide 18: Fourth Quarter and Full Year 2011 Financial Results